One hundred patients' experience with the Jyros valve.
The ideal mechanical valve abolishes all potential areas for blood stagnation and hence the potential for micro-emboli and clot formation. This problem has been addressed by the innovative design of the Jyros valve which has evolved from the technology available from Russian space research. The valve comprises two pyrolytic carbon leaflets which can rotate within the solid carbon housing to either align themselves to the optimum haemodynamic configuration, or to respond by rotation either continuous or intermittent, according to the degree of swirl on the inflow profile. This Jyros mechanical heart valve has been assessed in vivo at the London Chest Hospital since August 1992 where the series of unselected patients constitutes the largest single user experience available. 107 valves were implanted in 100 patients of age range 33 to 80 years. 23 patients were re-replacement for failed xenograft and 26 underwent concomitant revascularisation. 92 patients left hospital and 4 died later all from non-valve related causes. Two valves were explanted for endocarditis (one pre-existing) but successfully re-replaced. There have been no late thrombo-embolic events. Two patients with AVR & CABG had strokes at 8 months. There is no excessive haemolysis in excess of that detected for any mechanical valve nor any mechanical valve-related failure. Rotation of the valve is variable and can be visualised by 2D and M mode echo and by X-ray screening as the leaflets are impregnated with Boron carbide. Half of the valves rotate constantly and a quarter intermittently. There appears to be no disadvantage to patients in whom no valve rotation could be demonstrated. We have found that the theoretical potential of performance have been achieved.